Description
Thymosin Alpha-1 | Thymic Immunomodulatory Peptide — Research Grade
Thymosin Alpha-1 (Ta1) is a 28-amino acid N-acetylated peptide naturally secreted by thymic epithelial cells. It is the best-characterised component of Thymosin Fraction 5 and is approved as Zadaxin in over 35 countries for chronic hepatitis B and C, and as an adjunct in immunodeficiency states.
Mechanism of Action
- T-cell maturation and activation — promotes differentiation of T-helper and cytotoxic T-cell populations in thymic and peripheral models
- TLR-9 and TLR-2 signalling — activates Toll-like receptor pathways to prime innate immune responses
- Dendritic cell activation — enhances antigen presentation capacity and IL-12 production
- NK cell upregulation — studied for natural killer cell activity enhancement in cancer and viral infection models
Research Areas
Ta1 has been studied in chronic viral hepatitis, cancer immunology, sepsis, COVID-19 adjunct immunotherapy, and ageing-related immunosenescence. Extensive Phase II/III clinical data is available via the Zadaxin approval record.
For Research Use Only. Rainbow Peptide supplies Thymosin Alpha-1 exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. A. Okonjo –
Thymosin Alpha-1 used in our cytokine array and T-cell activation studies. This lot produced the expected immunomodulatory pattern with zero anomalies. Third-party COA verified our results. Endotoxin levels were within strict limits.
R. Nakamura –
Thymosin Alpha-1 lot tested at 98.7% HPLC. Clean mass spectrum, correct molecular weight confirmed. In vitro NK cell activation response matched published benchmarks. Excellent COA with full HPLC chromatogram.
T. Oberg –
Fourth order of Thymosin Alpha-1. Purity consistent above 98% across all batches. Supplier proactively sent documentation clarifying storage conditions after our inquiry. Excellent service and product quality.